DuPont Merck Studying Miraluma Imaging Agent In Patient Subgroups
This article was originally published in The Gray Sheet
Executive Summary
DuPont Merck has about 20 clinical trials under way with the breast cancer imaging agent Miraluma, the company says, including several looking at specific patient subgroups.